03.15.18
Dalton Pharma Services has signed a drug development and manufacturing services agreement with Oryn Therapeutics to provide drug development and cGMP aseptic liquid filling of Oryn’s ORTD-1 in glass vials for Phase I clinical studies.
ORTD-1 is a first-in-class drug for the treatment of rheumatoid arthritis (RA). ORTD-1 treatment of experimental arthritis in rats has been shown to induce remission of established disease after nine days of treatment, with remission lasting as long as 2-3 months after treatment is discontinued.
“Dalton is privileged to be associated with Oryn in its commitment to develop a safe and effective first-in-class drug treatment for RA,” said Peter Pekos, chief executive officer and president, Dalton Pharma Services.
ORTD-1 is a first-in-class drug for the treatment of rheumatoid arthritis (RA). ORTD-1 treatment of experimental arthritis in rats has been shown to induce remission of established disease after nine days of treatment, with remission lasting as long as 2-3 months after treatment is discontinued.
“Dalton is privileged to be associated with Oryn in its commitment to develop a safe and effective first-in-class drug treatment for RA,” said Peter Pekos, chief executive officer and president, Dalton Pharma Services.
